| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
97 |
| Employees |
299 |
| Revenues (TTM) (Millions $) |
379 |
| Net Income (TTM) (Millions $) |
-184 |
| Cash Flow (TTM) (Millions $) |
-211 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Myovant Sciences Ltd. is a United Kingdom-based pharmaceutical and healthcare company dedicated to developing and commercializing innovative medicines to improve the lives of women and men around the world. They focus on reproductive medicine, urology, and endocrinology, particularly on developing therapeutics which focus on hormonal conditions.
The company was founded in 2016 by Takeda Pharmaceutical Co. Ltd. and Roivant Sciences Ltd in order to combine Takeda's global resources and strategic focus on oncology with Roivant's expertise in a broad array of therapeutic areas. Since Roivant had a strong track record of bringing new drugs to market, Myovant Sciences was established to focus on developing and commercializing innovative medicines to address unmet needs in women's health and prostate cancer.
Their lead product candidate, Relugolix, is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which was developed to address unmet medical needs in women and men with hormone-related diseases. Relugolix is currently under review by regulatory authorities in the United States, Europe and Japan for the treatment of uterine fibroids, endometriosis, and advanced prostate cancer.
Myovant Sciences is also focused on developing and commercializing other innovative treatments for women's health conditions, such as menorrhagia, polycystic ovary syndrome (PCOS), and breast cancer. Their product portfolio includes several potential therapies in various stages of development, such as MVT-602, a kisspeptin agonist for controlled ovarian hyperstimulation in patients undergoing in vitro fertilization, and MVT-605, an oral selective estrogen receptor degrader (SERD) for the treatment of advanced breast cancer.
Through a series of partnerships and collaborations, Myovant Sciences has established a strong global presence, with operations in the United States, Japan, and Switzerland, and a network of partners across Europe and Asia. Their collaborations include an ongoing partnership with Pfizer to develop a drug for the treatment of uterine fibroids, a co-development and commercialization agreement with Sumitomo Dainippon Pharma for relugolix in Japan, and a strategic partnership with AbbVie for up to $4 billion to develop and commercialize relugolix in other indications such as endometriosis and uterine fibroids.
In addition to developing innovative medicines, Myovant Sciences is committed to positively impacting the communities it serves. They have established programs such as the Inspire Scholarship, which provides financial assistance to women pursuing graduate education in science, technology, engineering or math (STEM) fields, and partnerships with organizations such as the Black Women's Health Initiative and the National Organization for Rare Disorders (NORD) to create greater awareness of rare diseases and support patient advocacy efforts.
Overall, Myovant Sciences is a well-established pharmaceutical company that is focused on developing innovative treatments for hormone-related diseases in women and men, and is committed to delivering value to its stakeholders through partnerships, collaborations, and socially responsible initiatives.
Company Address: 50 Broadway London 0
Company Phone Number: 400 3351 Stock Exchange / Ticker: NYSE MYOV
|
%
0.38% 